The Process of Elimination

Incontinence represents a significant unmet medical need for 20 million Americans that suffer from urge incontinence, and 13 million sufferers of stress incontinence. The market is large, growing, and approachable for small device companies--if they can get funding, that is.

Incontinence is a particularly unglamorous sector of the medical device industry. Companies with innovative surgical approaches for shoring up a slack urethra or with cleverly designed gizmos that prevent the unintentional leakage of urine find themselves competing with such mundane treatment options as diapers and Kegel exercises. Incontinence is not a life and death issue. But to paraphrase a remark attributed to Bill George, CEO of Medtronic Inc. , incontinence is a matter of life or no life. Millions of people remain housebound out of fear that they cannot control their bladders. The condition represents a significant unmet medical need for 20 million Americans that suffer from urge incontinence, and 13 million suffers of stress incontinence in the US, the majority of them women. The numbers are on the rise, because these conditions become more common with aging.

The incontinence market represents a frontier in which small companies should be able to stake claims. It is not dominated...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

Executives On The Move: Three New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.